A detailed history of Prestige Wealth Management Group LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Prestige Wealth Management Group LLC holds 23 shares of NBIX stock, worth $2,886. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23
Previous 20 15.0%
Holding current value
$2,886
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$130.86 - $143.19 $392 - $429
3 Added 15.0%
23 $3,000
Q1 2024

Apr 26, 2024

SELL
$130.4 - $143.74 $2,347 - $2,587
-18 Reduced 47.37%
20 $2,000
Q4 2023

Apr 26, 2024

BUY
$106.07 - $132.76 $2,227 - $2,787
21 Added 123.53%
38 $5,000
Q4 2023

Feb 08, 2024

BUY
$106.07 - $132.76 $2,227 - $2,787
21 Added 123.53%
38 $5,000
Q3 2023

Apr 26, 2024

BUY
$94.02 - $117.1 $1,222 - $1,522
13 Added 325.0%
17 $1,000
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $1,222 - $1,522
13 Added 325.0%
17 $1,000
Q2 2023

Apr 26, 2024

SELL
$89.53 - $104.87 $1,611 - $1,887
-18 Reduced 81.82%
4 $0
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $1,611 - $1,887
-18 Reduced 81.82%
4 $0
Q1 2023

Apr 26, 2024

BUY
$94.11 - $123.02 $188 - $246
2 Added 10.0%
22 $2,000
Q1 2023

May 16, 2023

SELL
$94.11 - $123.02 $4,140 - $5,412
-44 Reduced 66.67%
22 $2,000
Q4 2022

Feb 07, 2023

BUY
$106.72 - $127.06 $2,881 - $3,430
27 Added 69.23%
66 $7,000
Q3 2022

Nov 01, 2022

BUY
$92.03 - $107.81 $552 - $646
6 Added 18.18%
39 $4,000
Q1 2022

May 05, 2022

BUY
$72.45 - $94.81 $2,390 - $3,128
33 New
33 $3,000
Q2 2021

Aug 12, 2021

SELL
$89.43 - $102.27 $5,991 - $6,852
-67 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$87.57 - $119.4 $2,014 - $2,746
23 Added 52.27%
67 $6,000
Q4 2020

Feb 17, 2021

BUY
$86.91 - $108.33 $3,824 - $4,766
44 New
44 $4,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Prestige Wealth Management Group LLC Portfolio

Follow Prestige Wealth Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prestige Wealth Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prestige Wealth Management Group LLC with notifications on news.